Hycamtin (Topotecan HCl) Patent Expiration, LOE Window & CMS Spending
Hycamtin (Topotecan HCl) by Sandoz: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $893K 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sandoz |
| FDA Application & Pathway | N020671 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Uncontested (0 AB Generics) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $893K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $893K |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 20.8% 2-yr change) |